Cargando…
Natural Products as a Novel Therapeutic Strategy for NLRP3 Inflammasome-Mediated Gout
Gout is the most common form of inflammatory arthritis. It occurs when monosodium urate crystals (MSU) are deposited within joints due to hyperuricemia and persistent elevations of serum uric acid levels. Traditional gout treatment such as urate-lowering therapy is difficult to continue for a long p...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967252/ https://www.ncbi.nlm.nih.gov/pubmed/35370689 http://dx.doi.org/10.3389/fphar.2022.861399 |
_version_ | 1784678801530159104 |
---|---|
author | Lee, Jun Ho Kim, Hyuk Soon Lee, Jun-Ho Yang, Gabsik Kim, Hong Jun |
author_facet | Lee, Jun Ho Kim, Hyuk Soon Lee, Jun-Ho Yang, Gabsik Kim, Hong Jun |
author_sort | Lee, Jun Ho |
collection | PubMed |
description | Gout is the most common form of inflammatory arthritis. It occurs when monosodium urate crystals (MSU) are deposited within joints due to hyperuricemia and persistent elevations of serum uric acid levels. Traditional gout treatment such as urate-lowering therapy is difficult to continue for a long period of time due to the risk of side effects. Recent studies have shown that the modulation of MSU-induced inflammatory responses is dependent on the inflammatory cytokine IL-1β, which has a central role in a chain of processes involving multiple cytokines and mediators. In this regard, the NLRP3 inflammasome is known to play a crucial part and thus has been proposed as a novel target in the treatment for gout. However, the biochemical mechanism for NLRP3 inflammasome activation has not yet been clearly elucidated. Therefore, this report can provide an overview of natural extractions targeted to prevent or treat NLRP3 inflammasome-mediated gout in the MSU-induced gout model. In addition, the research and development of such natural products are suggested as a potential strategy in the treatment of gout. |
format | Online Article Text |
id | pubmed-8967252 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89672522022-03-31 Natural Products as a Novel Therapeutic Strategy for NLRP3 Inflammasome-Mediated Gout Lee, Jun Ho Kim, Hyuk Soon Lee, Jun-Ho Yang, Gabsik Kim, Hong Jun Front Pharmacol Pharmacology Gout is the most common form of inflammatory arthritis. It occurs when monosodium urate crystals (MSU) are deposited within joints due to hyperuricemia and persistent elevations of serum uric acid levels. Traditional gout treatment such as urate-lowering therapy is difficult to continue for a long period of time due to the risk of side effects. Recent studies have shown that the modulation of MSU-induced inflammatory responses is dependent on the inflammatory cytokine IL-1β, which has a central role in a chain of processes involving multiple cytokines and mediators. In this regard, the NLRP3 inflammasome is known to play a crucial part and thus has been proposed as a novel target in the treatment for gout. However, the biochemical mechanism for NLRP3 inflammasome activation has not yet been clearly elucidated. Therefore, this report can provide an overview of natural extractions targeted to prevent or treat NLRP3 inflammasome-mediated gout in the MSU-induced gout model. In addition, the research and development of such natural products are suggested as a potential strategy in the treatment of gout. Frontiers Media S.A. 2022-03-16 /pmc/articles/PMC8967252/ /pubmed/35370689 http://dx.doi.org/10.3389/fphar.2022.861399 Text en Copyright © 2022 Lee, Kim, Lee, Yang and Kim. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Lee, Jun Ho Kim, Hyuk Soon Lee, Jun-Ho Yang, Gabsik Kim, Hong Jun Natural Products as a Novel Therapeutic Strategy for NLRP3 Inflammasome-Mediated Gout |
title | Natural Products as a Novel Therapeutic Strategy for NLRP3 Inflammasome-Mediated Gout |
title_full | Natural Products as a Novel Therapeutic Strategy for NLRP3 Inflammasome-Mediated Gout |
title_fullStr | Natural Products as a Novel Therapeutic Strategy for NLRP3 Inflammasome-Mediated Gout |
title_full_unstemmed | Natural Products as a Novel Therapeutic Strategy for NLRP3 Inflammasome-Mediated Gout |
title_short | Natural Products as a Novel Therapeutic Strategy for NLRP3 Inflammasome-Mediated Gout |
title_sort | natural products as a novel therapeutic strategy for nlrp3 inflammasome-mediated gout |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967252/ https://www.ncbi.nlm.nih.gov/pubmed/35370689 http://dx.doi.org/10.3389/fphar.2022.861399 |
work_keys_str_mv | AT leejunho naturalproductsasanoveltherapeuticstrategyfornlrp3inflammasomemediatedgout AT kimhyuksoon naturalproductsasanoveltherapeuticstrategyfornlrp3inflammasomemediatedgout AT leejunho naturalproductsasanoveltherapeuticstrategyfornlrp3inflammasomemediatedgout AT yanggabsik naturalproductsasanoveltherapeuticstrategyfornlrp3inflammasomemediatedgout AT kimhongjun naturalproductsasanoveltherapeuticstrategyfornlrp3inflammasomemediatedgout |